Verana Health Expands Bladder Cancer Database, Bolsters Genitourinary Cancer Research
Event summary
- Verana Health updated its real-world data (RWD) bladder cancer database on May 21, 2026, expanding its genitourinary cancer research capabilities.
- The database includes detailed clinical data such as T-stage, tumor focality, tumor grade, and tumor response for both non-muscle and muscle invasive bladder cancers.
- The expansion follows the introduction of the world's largest curated RWD prostate cancer dataset and the industry's first end-to-end urologic-oncology datasets.
- Verana Health's network access includes over 30 Academic Medical Centers and over 10 million accessible oncology patients post-COTA merger.
The big picture
Verana Health's expansion of its bladder cancer database underscores its strategic focus on leveraging real-world data to drive advancements in genitourinary cancer research. The company's exclusive partnership with the AUA Quality Registry and the recent COTA merger position it as a key player in the digital health space, providing comprehensive, granular insights into the patient journey. This move aligns with broader industry trends towards data-driven clinical research and evidence-based treatment decisions.
What we're watching
- Data Integration
- How Verana Health will leverage its extensive partnership network to link disease-specific EHR data with other sources for a deeper understanding of the full patient journey.
- Regulatory Submissions
- Whether the expanded bladder cancer database will accelerate evidence generation for regulatory submissions and commercialization decisions in the life sciences industry.
- Market Position
- The pace at which Verana Health can sustain its leadership in genitourinary cancer research following the COTA merger and database expansions.
Related topics